You are required to be logged in to access the full website
User Name: Password:
Click here if you have forgotten your username or password
  • Home
  • Latest News
  • Search
  • About M2 Pharma
  • Subscribe
Business & Finance
Generics
Therapy Areas
Policy & Regulation
Research & Development
People
Research & Development
Veralox Therapeutics Submits IND to US FDA for Phase I Trial of VLX-1005 to Treat Heparin-Inducted Thrombocytopenia
Login
Username:

Password:


Related Headlines

Clene Inc closes registered direct offering of common stock to existing shareholders

Beacon Therapeutics reports positive topline results from VISTA trial in X-linked retinitis pigmentosa

Insmed's ARIKAYCE sNDA granted priority review by FDA

Precigen announces FDA platform technology designation for AdenoVerse

Enhertu recommended for EU approval in early HER2-positive breast cancer

PureTech receives FDA Fast Track designation for LYT-200 in HR-MDS

Zealand Pharma's Zeydovio (glepaglutide) receives positive CHMP opinion for short bowel syndrome treatment

MaaT Pharma outlines potential Phase 3 development plan for MaaT013 after CHMP negative opinion

Bayer's Kerendia wins FDA approval for chronic kidney disease associated with type 1 diabetes

Myosin Therapeutics chosen for 2026-2027 NCI Investor Initiatives Showcase

Medtronic receives FDA clearance for LigaSure RAS Maryland instrument on Hugo system

VaxThera partners with Codagenix for next generation yellow fever vaccine advancement

MaaT Pharma receives negative CHMP trend vote for MaaT013

FDA approves Scholar Rock's ISEMBYLD to treat spinal muscular atrophy

FDA grants priority review to Takeda's zasocitinib application for plaque psoriasis

Home | Business & Finance | Generics | Therapy Areas | Policy & Regulation | Research & Development | People | Search | About M2 Pharma | Subscribe
Copyright © 2026